Claims for Patent: 6,099,838

Summary for Patent: 6,099,838

Title:	Pharmaceutical compositions comprising anti-CD45RB antibodies for the inhibition of T-cell mediated immune responses
Abstract:	Compositions comprising anti-CD45RB antibodies are provided for the prevention or reversal of transplant rejection as well as therapy for autoimmune diseases.
Inventor(s):	Lazarovits; Andrew I. (London, CA), Poppema; Sibrand (Edmonton, CA)
Assignee:	Reasearch Corporation Technologies, Inc. (Tucson, AZ)
Application Number:	09/018,282
Patent Claims:	1. A pharmaceutical composition comprising an amount of a monoclonal antibody, a fragment thereof or a mixture thereof that specifically binds to the CD45RB epitope of the CD45RB isoform of the leukocyte common antigen, wherein said amount is effective to inhibit a T-cell mediated immune response in a recipient to a tissue or organ transplant. 2. A pharmaceutical composition, comprising an amount of a monoclonal antibody, a fragment thereof or a mixture thereof which specifically binds to the CD45RB epitope of the CD45RB isoform of the leukocyte common antigen, wherein said amount is effective to inhibit a T-cell mediated immune response in an animal having an autoimmune disease. 3. The pharmaceutical composition of claim 1 or 2 which comprises an anti-CD45RB monoclonal antibody. 4. The pharmaceutical composition of claim 1 wherein the recipient is a human. 5. The pharmaceutical composition of claim 2 wherein the animal is a human. 6. The pharmaceutical composition of claim 1 wherein the amount is effective to induce immune tolerance in the recipient to the transplant. 7. The pharmaceutical composition of claim 1, wherein said tissue or organ transplant is allogeneic to the recipient. 8. The pharmaceutical composition of claim 2 wherein the autoimmune disease is inflammatory bowel disease, multiple sclerosis, Type I diabetes, systemic lupus erythematosus or rheumatoid arthritis. 9. The pharmaceutical composition of claims 1 or 2 which is adapted for parenteral administration. 10. The pharmaceutical composition of claim 9, which is adapted for intravenous administration. 11. The pharmaceutical composition of claims 1 or 2, which comprises an aqueous carrier. 12. The pharmaceutical composition of claim 11 wherein the carrier is sterile water. 13. The pharmaceutical composition of claim 11 wherein the carrier is buffered physiological saline. 14. The pharmaceutical composition of claim 13 which further comprises human serum albumin. 15. The pharmaceutical amount of claims 1 or 2 wherein the composition provides a dose of 0.01-5 mg/kg of said monoclonal antibody, said fragment thereof or said mixture thereof. 16. The pharmaceutical composition of claims 1 or 2 which comprises 0.5-250 mg of said monoclonal antibody, said fragment thereof or said mixture thereof.

Details for Patent 6,099,838

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2013-06-02